Empagliflozin belongs to a class of substances called hypoglycemic agents, which lower glucose levels in the blood. It is indicated as an adjunct to diet and exercise to improve glycemic (blood sugar) control in adults with type 2 diabetes mellitus.
Type 2 diabetes mellitus is a metabolic disorder characterized by high blood sugar in the context of insulin resistance and relative lack of insulin. Orally administered, Empagliflozin exerts its therapeutic effect by inhibiting sodium-glucose co-transporter 2 (SGLT2).
Developed by Boehringer Ingelheim and Eli Lilly and Company, Empagliflozin was approved in the United States and Europe in 2014. It is prepared through a stepwise organic synthetic procedure.